Ovchinnikov A G, Skorobogatova A V, Seiniglazova T Yu, Kozyavin N A, Ageev F T, Chazova I E
Vopr Onkol. 2016;62(6):719-731.
The review discusses mechanisms of trastuzumab cardio- toxicity. There are presented risk factors of development of the left ventricular dysfunction in treatment of a drug, among which the most important are the simultaneous administration of anthracycline antibiotics and the presence of associated cardiovascular diseases. There are discussed the features of cardiac management of patients receiving trastuzumab therapy that focuses on early detection of abnormalities of left ven- tricular function from the normality as well as measures aim- ing at preventing the occurrence of cardiac dysfunction and its treatment.
该综述讨论了曲妥珠单抗心脏毒性的机制。文中介绍了使用该药物治疗时发生左心室功能障碍的风险因素，其中最重要的是同时使用蒽环类抗生素以及存在相关心血管疾病。还讨论了接受曲妥珠单抗治疗患者的心脏管理特点，重点是早期发现左心室功能与正常情况的异常，以及旨在预防心脏功能障碍发生及其治疗的措施。
